OR WAIT null SECS
- Advertise
- About Us
- Editorial Board
- Contact Us
- Job Board
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Infection Control Today. All rights reserved.
Silvasorb Antimicrobial Silver Wound Dressing Receives 2003 Technological Innovation Award
MUNDLEIN, Ill. -- Frost & Sullivan recently announced AcryMed, Inc. as the recipient of the 2003 Technological Innovation Award in the antimicrobial dressings market. The award specifically recognizes AcyMed's development of its MicroLattice technology used in the company's line of SilvaSorb Silver Antimicrobial Dressings. Medline Industries, Inc. is the exclusive distributor of
SilvaSorb in the U.S. SilvaSorb is a major addition to Medline's family of controlled-release silver wound care products, including Arglaes.
In a recent study titled "U.S. Antimicrobial Devices Market," Frost & Sullivan acknowledged AcryMed's demonstrated technological superiority within the industry.
SilvaSorb is a sterile, single use wound dressing for use in moist wound management. It combines patented MicroLattice technology with the unique, stabilized sustained release silver technology for an effective dressing of up to seven days. The MicroLattice synthetic matrix helps to maintain an optimal environment for healing by managing the moisture level in the wound. MicroLattice either donates moisture if required or absorbs up to five times its weight in excess wound exudate. It also controls the release of ionic silver when triggered by contact with moisture.
"SilvaSorb is the first wound care dressing to help control the bioburden in a wound and at the same time maintain the right level of moisture for an optimal wound healing environment," said Jonathan Primer, president of Medline's Dermal Management Division. "To heal efficiently, chronic wounds require fluid management and bioburden reduction without destroying healthy tissue - SilvaSorb accomplishes all of this."
As an effective barrier to a broad spectrum of microorganisms, SilvaSorb may help reduce infection by inhibiting the growth of Staphylococcus aureus, including MRSA, Pseudomonas aeruginosa, Escherichia coli, Candida albicans, VRE, and other clinically significant microorganisms.
SilvaSorb comes in a variety of formats for optimal use in the management of a variety of wound types such as pressure ulcers, diabetic foot ulcers, leg ulcers, skin tears, first and second degree burns, grafted wounds and donor sites, surgical wounds, and lacerations and abrasions.
Similar to SilvaSorb, Arglaes uses controlled release technology to deliver silver onto the application site. Arglaes is used effectively to help reduce infection on post surgical incision sites, central line sites, pressure ulcers and minor burns. In addition to a transparent film dressing, Arglaes now comes in a powder form to deliver controlled-release antimicrobial silver to any size, shape or depth of wound.
The Frost & Sullivan Technological Innovation Award is presented each year to the company that has best demonstrated the ability to successfully develop and introduce new technology, formulating a well-designed product family. The recipient company's technology is expected to make significant product performance contributions to the industry.
AcryMed is a rapidly growing biomaterials and medical device company based in Portland, Oregon. AcryMed specializes in the development and manufacturing of advanced tissue repair products from its patented core technologies.
